188 related articles for article (PubMed ID: 36348234)
1. Progressive multifocal leukoencephalopathy, advanced ductal breast carcinoma, systemic sclerosis, and checkpoint inhibitors: a therapeutic dilemma.
Baena-Álvarez B; Rodríguez-Jorge F; Beltrán-Corbellini Á; Cortés-Salgado A; De la Puente C; Corral Í
J Neurovirol; 2023 Feb; 29(1):116-119. PubMed ID: 36348234
[TBL] [Abstract][Full Text] [Related]
2. Progressive multifocal leukoencephalopathy in systemic lupus erythematosus managed with pembrolizumab: A case report with literature review.
Lan TY; Chen YS; Cheng CF; Huang ST; Shen CY; Hsu PN
Lupus; 2021 Oct; 30(11):1849-1855. PubMed ID: 34325541
[TBL] [Abstract][Full Text] [Related]
3. Progressive multifocal leukoencephalopathy secondary to idiopathic CD4 lymphocytopenia treated with pembrolizumab.
Varmpompiti K; Westwood AJ; Ben-Joseph A; Sibtain N; Ibrahim MAA; Stanton B; Zuckerman M; Hadden R; Ritter LM
J Neuroimmunol; 2023 Dec; 385():578248. PubMed ID: 37995595
[TBL] [Abstract][Full Text] [Related]
4. Probable progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with immunosuppressant dose reduction following lung transplantation: a case report and literature review.
Ishii K; Yamamoto F; Homma S; Okada Y; Nakamichi K; Saijo M; Tamaoka A
BMC Neurol; 2019 Oct; 19(1):263. PubMed ID: 31672142
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab treatment of inflammatory progressive multifocal leukoencephalopathy: a report of two cases.
Darcy S; Alexander M; McCarthy A; O'Dowd S
J Neurovirol; 2022 Feb; 28(1):145-150. PubMed ID: 34874539
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy.
Cortese I; Muranski P; Enose-Akahata Y; Ha SK; Smith B; Monaco M; Ryschkewitsch C; Major EO; Ohayon J; Schindler MK; Beck E; Reoma LB; Jacobson S; Reich DS; Nath A
N Engl J Med; 2019 Apr; 380(17):1597-1605. PubMed ID: 30969503
[TBL] [Abstract][Full Text] [Related]
7. The spectrum of progressive multifocal leukoencephalopathy: a practical approach.
Bartsch T; Rempe T; Leypoldt F; Riedel C; Jansen O; Berg D; Deuschl G
Eur J Neurol; 2019 Apr; 26(4):566-e41. PubMed ID: 30629326
[TBL] [Abstract][Full Text] [Related]
8. Sequential treatment of progressive multifocal leukoencephalopathy with intravenous immunoglobulins and pembrolizumab.
Boesl F; Allers K; Herm J; Scheider T; Franke C
J Neurovirol; 2022 Apr; 28(2):335-338. PubMed ID: 35320511
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab for treatment of progressive multifocal leukoencephalopathy in primary immunodeficiency and/or hematologic malignancy: a case series of five patients.
Volk T; Warnatz K; Marks R; Urbach H; Schluh G; Strohmeier V; Rojas-Restrepo J; Grimbacher B; Rauer S
J Neurol; 2022 Feb; 269(2):973-981. PubMed ID: 34196768
[TBL] [Abstract][Full Text] [Related]
10. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy.
Du Pasquier RA; Kuroda MJ; Zheng Y; Jean-Jacques J; Letvin NL; Koralnik IJ
Brain; 2004 Sep; 127(Pt 9):1970-8. PubMed ID: 15215217
[TBL] [Abstract][Full Text] [Related]
11. Severe Progressive Multifocal Leukoencephalopathy (PML) and Spontaneous Immune Reconstitution Inflammatory Syndrome (IRIS) in an Immunocompetent Patient.
Krey L; Raab P; Sherzay R; Berding G; Stoll M; Stangel M; Wegner F
Front Immunol; 2019; 10():1188. PubMed ID: 31191548
[No Abstract] [Full Text] [Related]
12. Promise and Challenges of Checkpoint Inhibitor Therapy for Progressive Multifocal Leukoencephalopathy in HIV.
Corey S; Smith BR; Cortese ICM
Curr HIV/AIDS Rep; 2022 Dec; 19(6):580-591. PubMed ID: 36181625
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy: a new gold standard?
Roos-Weil D; Weiss N; Guihot A; Uzunov M; Bellanger A; Eymard B; Saadoun D; Houillier C; Idbaih A; Demeret S; Deback C; Leblond V; Galanaud D; Shor N; Pourcher V
J Neurol; 2021 Jul; 268(7):2458-2465. PubMed ID: 33515299
[TBL] [Abstract][Full Text] [Related]
14. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain.
Ferenczy MW; Marshall LJ; Nelson CD; Atwood WJ; Nath A; Khalili K; Major EO
Clin Microbiol Rev; 2012 Jul; 25(3):471-506. PubMed ID: 22763635
[TBL] [Abstract][Full Text] [Related]
15. Molecular regulation of JC virus tropism: insights into potential therapeutic targets for progressive multifocal leukoencephalopathy.
Marshall LJ; Major EO
J Neuroimmune Pharmacol; 2010 Sep; 5(3):404-17. PubMed ID: 20401541
[TBL] [Abstract][Full Text] [Related]
16. Checkpoint inhibitors for the treatment of JC virus-related progressive multifocal leukoencephalopathy.
Beck ES; Cortese I
Curr Opin Virol; 2020 Feb; 40():19-27. PubMed ID: 32279025
[TBL] [Abstract][Full Text] [Related]
17. A human T-lymphotropic virus-1 carrier who developed progressive multifocal leukoencephalopathy following immunotherapy for sarcoidosis: a case report.
Nagahori T; Shiraishi W; Nishikawa M; Matsuyoshi A; Ogura T; Yamada Y; Takahashi K; Suzuki T; Nakamichi K; Hashimoto T; Hatano T
BMC Neurol; 2023 Feb; 23(1):52. PubMed ID: 36726087
[TBL] [Abstract][Full Text] [Related]
18. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
[TBL] [Abstract][Full Text] [Related]
19. Course of neuropsychological impairment during natalizumab-associated progressive multifocal leukoencephalopathy.
Kinner M; Prehn C; Schneider R; Schroeder C; Kolb E; Gold R; Hoepner R; Chan A
Eur J Neurol; 2021 Mar; 28(3):921-927. PubMed ID: 33085811
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy: Identifying relevant outcome factors.
Lambert N; El Moussaoui M; Maquet P
Eur J Neurol; 2021 Nov; 28(11):3814-3819. PubMed ID: 34251719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
